No Results Found
Try adjusting your search to find what you’re looking for.
8/04/2022
Illumina Ventures Announces Expansion Of Its Europe Team
Illumina Ventures announced the addition of four new members to its European team. Arnaud Autret, PhD, MSc, will be Principal and Head of European Operations, William Byrne, PhD, be an Associate – Europe, and Ronan Byrne and Ivan Coulter, PhD, BSc, will serve as Venture Advisors – Europe.
Read More
5/04/2022
Illumina Ventures Announces Promotion and Additions to its Investment Team
Illumina Ventures, today announced the promotion of Malek Faham, MD, PhD, to Chief Scientist having previously served as both a Venture Partner and Entrepreneur in Residence (EIR). In addition, Charles Lin, PhD, has joined the team as a Principal, and Dave Johnson, PhD, has joined as an Entrepreneur in Residence.
Read More
10/06/2021
NVCA Member Spotlight: Illumina Ventures
National Venture Capital Association interviews Nick Naclerio, Founding Partner at Illumina Ventures, to learn more about the firm... Illumina Ventures invests in early-stage life science companies with a particular focus on genomics and precision health. Our team and our unique relationship with Illumina, Inc. (NASDAQ: ILMN) is what sets us apart from other firms. Our members have been both ...
Read More
9/20/2021
Illumina Ventures Closes $325 Million Fund
Illumina Ventures, an independently managed, healthcare-focused venture firm, announced today the closing of its second investment fund with total commitments of $325 million, bringing its total capital under management to $560 million. The latest fund is anchored by Illumina, Inc. (Nasdaq: ILMN), with the majority of the total committed capital from other strategic and financial investors, ...
Read More